Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa.

Freeman, Esther E; White, Richard G; Bakker, Roel; Orroth, Kate K; Weiss, Helen A; Buvé, Anne; Hayes, Richard J; Glynn, Judith R; (2009) Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine, 27 (6). pp. 940-946. ISSN 0264-410X DOI: https://doi.org/10.1016/j.vaccine.2008.11.074

Abstract

Herpes simplex virus type-2 (HSV2) infection increases HIV transmission. We explore the impact of a potential prophylactic HSV2 vaccination on HIV incidence in Africa using STDSIM an individual-based model. A campaign that achieved 70% coverage over 5 years with a vaccine that reduced susceptibility to HSV2 acquisition and HSV2 reactivation by 75% for 10 years, reduced HIV incidence by 30-40% after 20 years (range 4-66%). Over 20 years, in most scenarios fewer than 100 vaccinations were required to avert one HIV infection. HSV2 vaccines could have a substantial impact on HIV incidence. Intensified efforts are needed to develop an effective HSV2 vaccine.

Additional Information

Item Type	Article
Faculty and Department	Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
Research Centre	Centre for Maternal, Reproductive and Child Health (MARCH) Vaccine Centre Tropical Epidemiology Group
PubMed ID	19071187
ISI	263421800018
Related URLs	OA Location